Cyviz Unveils Containerized C2 Solution During HEIMDALL
26.2.2026 12:00:00 EET | Business Wire | Press release
During Exercise HEIMDALL, organized by the Norwegian Joint Headquarters (FOH/NJHQ) this week, Cyviz is presenting its fully integrated, containerized solution for command, control, and collaboration environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226587573/en/
From deployment to operations: Cyviz’ container‑based C2 solution demonstrated during Exercise HEIMDALL. James Munt, Sales Director from Cyviz, took part in the demonstration.
The solution is designed for secure, standardized, and agile operations, enabling operators to fight at the edge with assured information and supporting faster decision-making, in line with the company’s strategic focus on the defense and security sector.
The container solution has been developed in collaboration with Nordic Shelter, providing the container platform. The modular platform combines control room technology, visualization, and software into one integrated system. It’s the first live demonstration in a NATO‑secure exercise environment.
Exercise HEIMDALL is conducted within a NATO-relevant framework and focuses on cooperation, technology, and operations in demanding environments.
– This is the first time we are demonstrating our containerized solution in an operational context. It's an important step in the continued development of standardized, secure solutions for defense environments, says Thomas Edberg, VP, Product at Cyviz.
Standardized for mission-critical environments
The container solution is developed as a standardized Commercial off‑the‑Shelf (COTS) platform designed to reduce complexity, risk, and deployment time in mission‑critical environments.
The architecture is secure by design, tailored for multi‑classification use cases, and built to meet strict security and availability requirements, including readiness for TEMPEST B certification and clearance up to NATO TS.
Cyviz delivers the complete technology stack in the container, including solutions for command and control, situational awareness, visualization, and software to manage complex environments.
– Defense and security organizations increasingly require standardized solutions that can be deployed rapidly while meeting high security standards. This solution is designed to address those needs, Edberg adds.
Defense as a strategic priority
Defense and security are strategic growth areas for Cyviz. With a proven track record of delivering mission-critical solutions to government and defense customers across several NATO member countries, the company is seeing growing demand driven by increased European defense investments, geopolitical uncertainty, and ongoing modernization initiatives.
– Our ambition is to be a long‑term technology partner for defense and security organizations with complex operational requirements, says James Munt, Sales Director at Cyviz.
Cyviz’ participation in Exercise HEIMDALL underscores the company’s position as a Norwegian defense supplier delivering secure, mission‑critical solutions and marks an important step in the continued development of containerized command and collaboration environments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226587573/en/
Contacts
Meylin S. Loo
Head of Communication & PR
+4745865411
Meylin.Loo@cyviz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 14:00:00 EET | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Unlike high-performance racing watches that can feel overwhelming,
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 14:00:00 EET | Press release
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs. With this acquisition, if completed, we will strengthen our armamentari
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 13:49:00 EET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants26.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13, 2025, for proceeds of approximately $200 million. Upon exercise of these outstanding warrants, Compass Pathways is issuing 15,160,619 American Depositary Shares (“ADSs”) and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass Pathways currently intends to use the proceeds from these warrant exercises, together with its existing cash and cash equivalents, to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in PTSD, acceleration of its commercial readiness activities, and for working capital and general corporate purposes. The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on Februar
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership26.2.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025. “These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA has firmly established itself as the global leader in the BTK inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in CLL. At the same time, we are securing new indications and expanded reimbursement for TEVIMBRA across key markets worldwide. With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom